The present teachings relates generally to biological and bioengineered fluids, and particularly to a method and apparatus for collection, concentration, and application of such a fluid.
Various fluids, such as whole blood or various other biological fluids may be separated into their constituent parts, also referred to as fractions or phases. For example, whole blood samples may include a plurality of constituents that may be separated by density in a device such as a centrifuge. The whole blood sample may be placed in a test tube, or other similar device, which is then spun in a centrifuge. In the centrifuge the whole blood is separated into different fractions depending upon the density of that fraction. In addition, various elements may be added to the test tube to create more than two fractions. In particular, commonly used gels may be used to divide the whole blood into a plurality of different fractions which may include fractions such as buffy coat platelets, red blood cells, and plasma. Various other biological fluids may be separated as well. For example, nucleated cells may be separated and extracted from bone marrow or adipose tissue sample.
A method and apparatus for collecting, concentrating, and applying a biological or bio-engineered fluid. Generally, the fluid application device includes a nozzle operable to enable the application of the fluid and a container adaptable to enable the separation of the fluid into at least a first component and a second component. The container can be releasably coupled to the nozzle. The nozzle can withdraw at least one of the first component or the second component from the container after the fluid has been separated to apply a portion of the fluid to a selected site.
A system for separating and applying a fluid is provided. The system can include a tube having a first part, a sterile container having a second part interconnected with said first part and a fluid transfer device. The tube can be removably positioned in the sterile container to maintain a sterility of a portion of the tube. The fluid transfer device can be operable to transfer a fluid into the tube while the sterility of a portion of the tube is maintained by interconnecting said fluid transfer device with said second port, and the fluid can be separated while the tube is disposed in the sterile container.
A method of separating a multi-component fluid in a container and dispensing at least one component from the container is provided. The selected component may be mixed with a second fluid. The method can include forming a first fraction and a second fraction by centrifuging the multi-component fluid disposed in the container and connecting the container to a spray assembly. The method further includes withdrawing at least a portion of the first fraction or second fraction via the spray assembly.
Also taught according to various embodiments is a method of withdrawing a material directly from a patient and collecting a selected fraction of the material for later use. The method can include filling a collection container with the material while the collection container is disposed in a sterile container. Further taught is separating the material in the collection container while the collection container is within the sterile container to form the selected fraction. Additionally, the method includes removing the collection container from the sterile container, and connecting the collection container to a spray nozzle to dispense at least the selected fraction.
Also provided in various embodiments is a nozzle assembly for dispensing a fluid. The nozzle assembly may include a first opening to communicate with a first fluid and a second opening to communicate with a second fluid. The second opening can define a passageway for the second fluid. The first opening and second opening can enable the first fluid and second fluid to mix external to the nozzle assembly.
Further areas of applicability of the present teachings will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and various examples, while indicating various embodiments, are intended for purposes of illustration only and are not intended to limit the scope of the teachings.
The present teachings will become more fully understood from the detailed description and the accompanying drawings, wherein:
The following description of various embodiments is merely exemplary in nature and is in no way intended to limit the teachings, its application, or uses. Although the following description exemplary refers to blood separation, it will be understood that the present teachings may be used to separate and concentrate any appropriate material, such as bone marrow aspirate, adipose tissue, etc. It will be further understood that many multi-component or multi-fraction fluids may be separated. The components or fractions are generally inter-mingled in the whole sample but may be separated with a centrifuge device that causes increased local gravity or gravitational forces. Also, various portions, according to various embodiments, may be changed and specialized depending upon the material being separated. Although the following description will relate to the separation and application of a blood sample, it should be noted that numerous other materials could be utilized, and further, the description is understood to not limit the appended claims.
As will be discussed in more detail herein, a fluid application device 10 is taught. The fluid application device 10 includes a separating container 12 and a spray applicator 14. Both the spray applicator 14 and the separation container 12 can be provided in sterile containers that included ports to all materials to be added to them while maintaining the exterior sterility of the container. As taught further herein, the various sterile containers can include bags, rigid containers, or the like. Nevertheless, the various portions can be used to allow for the separation of a multi-component material put in a separation container 12, for use of filling the spray applicator 14 in a manner that allows for exterior sterility over the various portions. Therefore, a material can be added to the various portions of the device 10 while the exterior of the containers remain sterile so they can be easily passed into a sterile field. This can be used during a procedure when autologous materials are used so that the various portions of the device, such as the separation container 12, can be positioned in various apparati, such as a centrifuge, without requiring later sterilization of the container.
A fluid application device 10, exemplarily illustrated in
With reference to
The separator 12 may be spun at any appropriate rate in the centrifuge, such as in a range of about 1,000 to about 8,000 RPMs. This produces a force of about 65 to about 4500 times greater than the force of normal gravity, as generally calculated in the art, on the separator 12 and the blood sample placed in the separator 12. At this force, the more dense material in a whole blood sample is forced towards a bottom 20 of the tube 16. The dense material, such as red blood cells or a red blood cell fraction 28, collects on the tube bottom 20. The buoy 24 may be formed to have a density that is less than the red blood cell fraction 28, and thus it is forced in a direction toward the top 18 of the tube 16 in the centrifuge. Nevertheless, because the buoy 24 may also be formed to be denser than a plasma fraction 30, the buoy 24 may not reach the top 18 of the tube 16.
The forces also affect the tube wall 22. The forces compress the tube 16 linearly along axis A thereby bowing or flexing the tube wall 22. As the tube wall 22 compresses it increases the diameter of the tube 16 making it easier for the buoy 24 to move in the direction of the top 18 of the tube 16. In addition, a bottom face 32 of the buoy 24 defines an inverse cone and helps the initial upward movement of the buoy 24.
During the centrifuge process, the red bloods cells of the red blood cell fraction 28 force the buoy 24 in the direction of the top 18 of the tube 16 because the buoy 24 is less dense than the red blood cell fraction 28. Although the whole blood sample, including the red blood cells, is loaded above the buoy 24, the red blood cells are able to move between the buoy 24 and the tube wall 22 because the circumference of the buoy 24 is less than the internal circumference of the tube 16 and the tube flexes during centrifuging. The difference may be any appropriate dimension to assist in moving the buoy 24, while maintaining the separation of the material. During the centrifuge process the buoy 24 stops at an interface of the plasma fraction 30 and the red blood cell fraction 28 because of the selected or tuned density of the buoy 24, although any appropriate density can be chosen for the buoy 24.
With continuing reference to
The cap 26 serves to connect the tube 16 to the spray applicator 14. The cap 26 further includes a first outlet 46 and a second outlet 48. The first outlet 46 may comprise a formed cylindrical section 50, however, any other configuration can be used. The second outlet 48 can mate with the hose barb 34b. The first outlet 46 and second outlet 48 each extend through the cap 26. The cylindrical section 50 of the first outlet 46 is disposed within the tube 16 of the separator 12. The cylindrical section 50 on the first outlet 46 enables the withdrawal of the red blood cell fraction 28 from the tube 16 after separation of the fluid. The hose barb 34b and first and second outlets 46, 48 can be integrally formed with the cap 26 or can be fixedly attached in a post processing step, such as by adhesives. The cap 26 also includes a first annular lip 52 disposed on a side 54 of the cap 26 which interconnects the top 18 of the separator 12 to the cap 26. A second annular lip 56 on the side 54 of the cap 26 and a groove 58 created between the first and second annular lips 52, 56 enables the spray applicator 14 to be releasably attached to the cap 26, as will be described in greater detail below.
The cap 26 has a top surface 60 including a cylindrical protrusion 62 extending therefrom and including a throughbore 64. The cylindrical protrusion 62 includes a plurality of threads 62a that can mate with a nut 66 to couple the cylindrical protrusion 62 to a stabilizing rod 68 for packaging purposes, although such a stabilizing rod 68 is not necessary. The cylindrical protrusion 62 may be integrally formed with the cap 26, or may be attached to the cap 26 via an adhesive, for example.
A coupler 70 can releasably attach the spray applicator 14 to the separator 12. In particular, the coupler 70 can be annular and may include threads 72, a first annular lip 74 and a second annular lip 76 to releasably attach the cap 26 of the separator 12 to a housing 78 of the spray applicator 14. More specifically, the housing 78 of the spray applicator 14 may contain a plurality of threads 80 that are configured to mate with the threads 72 on the coupler 70. The first annular lip 74 is adapted to fit securely in the groove 58 of the cap 26, between the first and second annular lips 52, 56 of the cap 26. Although the coupler 70 can be used, according to various embodiments, other mechanisms may be used to fasten the separator 12 to the spray applicator 14, such as mechanical fasteners, a snap fit engagement mechanism, or the like. Optionally, the coupler 70 may form a vacuum seal between the spray applicator 14 and the separator 12.
The spray applicator 14 can be coupled via the cap 26 to the tube 16 to enable the withdrawal of a desired fraction of blood from the tube 16 for application of the selected blood fraction to a desired area. The spray applicator 14 includes the housing 78 and a trigger assembly 82 coupled to the housing 78. The housing 78 includes a first fluid assembly 84 and a second fluid assembly 86. The first fluid assembly 84 is coupled to the separator 12, and enables the extraction of either the red blood cell fraction 28 or plasma fraction 30 from the separator 12, as will be described in greater detail below.
The first fluid assembly 84 includes a first withdrawal tube 88 and a second withdrawal tube 90. The first withdrawal tube 88 is fluidly coupled to the first outlet 46 and the second withdrawal tube 90 is fluidly coupled to the second outlet 48. The first and second withdrawal tubes 88, 90 can be in communication with a selector valve 92. The selector valve 92 is configured to either mate with the first outlet 46 or second outlet 48 depending upon input received from a knob 94. The knob 94 is coupled to the selector valve 92 and extends outside the housing 78 of the spray applicator 14 to enable an operator of the fluid application device 10 to select the desired blood composition by using the knob 94. It should be noted that although the selector valve 92 and knob 94 may be two distinct pieces, according to various embodiments, the selector valve 92 and knob 94 can be formed as one piece.
The selector valve 92 is fluidly coupled to a first check valve 96. The first check valve 96 is retained in a first cup shaped housing 98, however any other suitable housing could be employed. The first cup shaped housing 98 is disposed in a first chamber 99. The first cup shaped housing 98 includes a bottom section 100 that is adapted to fit inside a first spring 102. The first spring 102 has a first end 104 configured for receipt of the bottom section 100 and a second end 106 configured to mate with a second cup shaped housing 108. The second cup shaped housing 108 includes a bottom section 110 that has a first cylindrical protrusion 112 adapted to mate with the second end 106 of the first spring 102. The second cup shaped housing 108 can couple the first fluid assembly 84 to the trigger assembly 82. The second cup shaped housing 108 includes an exterior ring 118 that is adapted to mate with the trigger assembly 82, as will be discussed in greater detail below.
The first fluid assembly 84 also includes an outlet 120 defined by the housing 78 and fluidly coupled to a chamber 122. In particular, the outlet 120 includes the chamber 122 at a first end 124 in which a check valve 126 is disposed. A spring 127 is positioned in the chamber 122 of the outlet 120, adjacent to the check valve 126, to provide a force to keep the check valve 126 in place.
An insert 128 is attached to a second end 130 of the outlet 120. Specifically, the insert 128 includes a ring 132 to enable the insert 128 to be pushed into the outlet 120 until the ring 132 abuts a first ridge 134 formed in the housing 78. The insert 128 further includes an interior passage 136 fluidly coupled to the chamber 122 of the outlet 120 for receipt of the selected blood composition. The insert 128 also includes a nozzle 138 having an exterior 140 and an interior 142. The exterior 140 is conical and enables the operator of the fluid application device 10 to apply the fluid close to a desired site on a patient. The interior 142 is conical in shape and creates a conical spray pattern which can improve mixing with a second fluid 144, as will be described in greater detail below. Alternatively, the interior 142 of the nozzle 138 could be cylindrical to enable pinpoint application of the first fluid. Although the outlet 120 is described according to various embodiments as distinct pieces, it shall be understood that the outlet 120 could be formed as one piece with the housing 78, and further that different configurations of the nozzle 138 may be employed.
The second fluid assembly 86 enables a second fluid to mix with the pre-selected blood from the first fluid assembly 84 in a selected ratio, such as about one to about ten. The second fluid assembly 86 includes a reservoir 146 for receipt of the second fluid. The second fluid may be any type of fluid, such as a coagulant, including a thrombin solution or the like, as will be described in greater detail below. The reservoir 146 may be formed as one piece with the housing 78 or may be a separate piece attached to the housing 78.
The reservoir 146 includes an inlet 148 for insertion of the second material therethrough. At the end of the reservoir 146 is a check valve 150 disposed in a chamber 152 coupled to or formed with the reservoir 146. The reservoir 146 and chamber 152 are generally located at an angle with respect to the separator 12, to facilitate the removal of the second fluid from the reservoir 146. A spring 154 abuts the check valve 150 to provide a force to keep the check valve 150 adjacent to the reservoir 146 and prevent the unwanted escape of the second fluid from the reservoir 146.
A stopper 156 is located in the chamber 152, and has a first end 158 adjacent to the spring 154. The stopper 156 further includes a second end 160 adjacent to a second spring 162. The first and second ends 158, 160 of the stopper 156 are generally cylindrical in shape, however, the second end 160 may be slightly larger than the first end 158 to prevent the second fluid from exiting the chamber 152.
The second spring 162 has a first end 164 that is adjacent to the second end 160 of the stopper 156 and a second end 166 which is configured to mate with a third cup shaped housing 168. The third cup shaped housing 168 includes a bottom section 170 having a first cylindrical protrusion 172 adapted to mate with the second end 166 of the second spring 162. The third cup shaped housing 168 is configured to couple the second fluid assembly 86 to the trigger assembly 82. The third cup shaped housing 168 includes an exterior ring 174 that is adapted to mate with the trigger assembly 82, as will be described in greater detail below.
The second fluid assembly 86 also includes an outlet passage 176 fluidly coupled to the chamber 152 to enable the second fluid to exit the reservoir 146. The outlet passage 176 may include a first passage 178 in fluid communication with a second passage 180. The first passage 178 intersects the chamber 152 and extends vertically therefrom, such that the first passage 178 is approximately parallel to the separator 12. The first passage 178 includes a first section 182 and a second section 184. The first section 182 is fluidly coupled to the chamber 152 and has a first diameter D1 which is smaller than a second diameter D2 of the second section 184, as illustrated in
The second passage 180 is fluidly coupled to the first passage 178 and includes a first chamber 190 extending substantially the length of the housing 78. The second passage 180 includes the first chamber 190 which generally intersects the first passage 178 at a selected angle and extends through the housing 78 to a second chamber 192 which is conical in shape. The second chamber 192 has an outlet 194 for dispensing the second fluid into the atmosphere.
Both the first fluid assembly 84 and the second fluid assembly 86 are each coupled to the trigger assembly 82. The trigger assembly 82 operates to control the flow of the fluids through the first fluid assembly 84 and second fluid assembly 86. The trigger assembly 82 includes a trigger connector 196 coupled to a trigger piece 198. The trigger connector 196 has a first end 200, a second end 202, and a third end 204. The first end 200 of the trigger connector 196 includes a cavity 206, which is generally cylindrical and includes an internal groove 208. The second cup shaped housing 108 of the first fluid assembly 84 is configured to interconnect and/or fit securely within the cavity 206. For example, the exterior ring 118 of the second cup shaped housing 108 may mate with the internal groove 208 of the cavity 206. The second end 202 of the trigger connector 196 includes an elongated cylinder 210 adapted to pivotably attach the trigger connector 196 to the trigger piece 198. The third end 204 includes a smaller cup shaped cavity 212 adapted to engage the second fluid assembly 86. The third cup shaped housing 168 of the second fluid assembly 86 can be configured to mate with the cavity 206 via an internal groove 214 formed in the cavity 212. In particular, the exterior ring 174 of the third cup shaped housing 168 is configured to engage the internal groove 214 of the cavity 212. Thus, both the first and second fluid assemblies 84, 86 are coupled to the trigger assembly 82 via the trigger connector 196.
The trigger piece 198 includes a housing 216 defined by a front surface 218, a left side 220 and a right side 222. The front surface 218 is generally flat to provide a surface for an operator to engage the trigger piece 198. The left and right sides 220, 222 each include a first ledge 224, and a second ledge 226 on an interior surface 228. The first and second ledges on the interior surface 228 are configured to guide the elongated cylinder 210 on the second end 228 of the trigger connector 196 into a curved piece 210 fixed to a rear surface 202 of the front surface 218. In particular, the curved piece 234 is adapted to fixedly receive the elongated cylinder 210 on the second end 228 of the trigger connector 196 and enables the elongated cylinder 210 to rotate within the curved piece 234 upon the depression of the trigger piece 198 by an operator. A first ridge 238 and a second ridge 240 are located on an exterior surface 242. The first and second ridges 238, 240 on the exterior surface 242 can provide a gripping surface. An interior plate 244 coupled to the interior surface 228 of the left and right sides 220, 222 rests against a surface 218 when the trigger piece 198 is in a first stationary position and prevents the trigger piece 198 from rotating forward.
The left and right sides 220, 222 of the trigger piece 198 each further include a cylindrical cavity 246 formed in a top section 248 of each of the left and right sides 220, 222. The cylindrical cavities 246 are adapted to mate with a plunger assembly 248 that serves to removably and rotatably attach the trigger piece 198 to the housing 78. In particular, the plunger assembly 248 includes two plungers 250, each plunger 250 is adapted to compress and then lock into place within the corresponding cylindrical cavities 246 in the left and right sides 220, 222 of the trigger piece 198. The fit of the plungers 250 in the cylindrical cavities 246 is such that it allows the trigger piece 198 to rotate when the trigger piece 198 is depressed by an operator. Thus, the first check valve 96, first cup shaped housing 98, first spring 102, second cup shaped housing 108 and trigger connector 196 enable the selected blood to enter the chamber 99 when the trigger piece 198 is depressed.
In addition, as best shown in
Typically, the second nozzle 256 includes an interior tapered portion 260 configured to enable the second nozzle 256 to spray the first fluid into the atmosphere in a mist, as best shown in
With continuing reference to
More specifically, the first syringe 302 may be used to withdraw the blood sample from a patient and may include a first fluid 320 as shown in
With reference now to
The spray applicator 14 can also be provided in a sterile bag 308c. The sterile bag 308c can include a port 309c that can allow for introduction of a material into the reservoir 146 of the spray applicator 14. The material can be any appropriate material, such as autologous thrombin, xenographic thrombin, or other appropriate materials. If autologous thrombin is used, the material can be obtained from the patient in a substantially sterile fashion and introduced into the spray applicator 14 through the port in the sterile bag 308c. Therefore, the material that is positioned in the spray applicator 14 can also be introduced into the spray applicator 14 in a substantially sterile manner and the spray applicator 14 can be delivered near the sterile field in the sterile bag 308c also in a substantially sterile manner. Therefore, the material can be provided to the spray applicator 14 and other sterilization steps are not required.
The second syringe 304 can be used to create the second fluid. Specifically, the second syringe 304 can include a third fluid 324, such as, for example, calcium chloride (CaCl2) or any other similar material which can react with a solid material 326 in the vial 306 to form a solution. The vial 306 may also be contained in a sterile bag 308b. The vial 306 may have an opening 328 that enables the receipt of the second syringe 304 therein, but prevents the escape of fluid therefrom. A plunger 330 on the second syringe 304 can then be depressed to release the third fluid 324 into the vial 306 via the port 309b on the sterile bag 308b. The vial 306 can then be shaken if necessary to mix the solid material 326 with the third fluid 324. The solid material 326 may be a clotting agent, such as, for example, thrombin. Thus, the third fluid 324 and solid material 326 may be used to make the second fluid, a thrombin solution, for example, which can then be withdrawn from the vial 306 via the port 309b on the sterile bag 308b. The second syringe 304, when filled to a desired level, can then deposit the solution of the third fluid 324 and the solid material 326 into the reservoir 146 of the spray applicator 14, through the port 309c on the sterile bag 308c. The second fluid can also be formed from a portion of the blood withdrawn from the patient or from another source, such as bovine blood.
With continuing reference to
As the trigger piece 198 begins to move back into its rest position, the spring 154 in the chamber 152 begins to decompress and the check valve 150 adjacent to the reservoir 146 moves to enable the second fluid to enter the chamber 152. Simultaneously, the second fluid in the chamber 152 will begin to enter into the first passage 178 of the outlet passage 176 due to the pressure differential which exists between the chamber 152 and the first passage 178. As the second fluid moves up the first passage 178, the pressure of the fluid causes the check valve 186 to move, and enables the fluid to engage the stopper 156. Once the stopper 156 is displaced, the second fluid can exit the first passage 178 and enter the second passage 180 prior to being expelled into the atmosphere via either the outlet 194 or the trough 258 of the first nozzle 254 of the nozzle assembly 252 as shown in
With reference now to
The fluid application device 10 enables an operator to spray an operation site with either red blood cell fraction 28 or plasma fraction 30 and a coagulant prior to closing the incision. More specifically, the nozzle assembly and nozzle of the insert and outlet of the second fluid assembly enable the blood and second fluid to mix external of the fluid application device 10, which helps eliminate the chances of clogging. In addition, the ability to attach a spray applicator to a separator tube which has been centrifuged reduces the complexity of current systems which require numerous steps prior to being able to use the separated blood. In addition, the sterile bags 308a, 308b, 308c ensure the sterility of the separator 12, spray applicator 14 and vial 306 both internally and externally, and permit the centrifugation of the separator 12 while the separator 12 is maintained in the sterile bag 308a. The use of the fluid application device 10 of the present invention thus not only reduces the complexity of current systems but also increases the efficiency of the process by enabling a one step process to access the separated blood while reducing clogging.
The description of the teaching is merely exemplary in nature and, thus, variations that do not depart from the gist of the teachings are intended to be within the scope of the teachings. Such variations are not to be regarded as a departure from the spirit and scope of the teachings.
This application is a divisional of U.S. patent application Ser. No. 12/832,293 filed on Jul. 8, 2010, which is a divisional of U.S. patent application Ser. No. 11/222,303 filed on Sep. 8, 2005, now U.S. Pat. No. 7,766,900 issued on Aug. 3, 2010, which claims the benefit of U.S. Provisional Application No. 60/654,720 filed on Feb. 21, 2005. The disclosures of the above applications are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1378806 | Ausubel | May 1921 | A |
1948388 | Liberson | Feb 1934 | A |
1950137 | Dowe | Mar 1934 | A |
2112160 | Johnson | Mar 1938 | A |
2322753 | Thomas | Jun 1943 | A |
2533004 | Ferry et al. | Dec 1950 | A |
2915063 | Cutter | Dec 1959 | A |
RE25113 | Wilburn | Jan 1962 | E |
3112747 | Cowley | Dec 1963 | A |
3215141 | Podhora | Nov 1965 | A |
3223083 | Cobey | Dec 1965 | A |
3236418 | Dalle et al. | Feb 1966 | A |
3314427 | Stafford | Apr 1967 | A |
3406686 | Keller | Oct 1968 | A |
3435944 | Ishii | Apr 1969 | A |
3467096 | Horn | Sep 1969 | A |
3473646 | Burke | Oct 1969 | A |
3552394 | Horn | Jan 1971 | A |
3586064 | Brown et al. | Jun 1971 | A |
3625353 | Ishii | Dec 1971 | A |
3654925 | Holderith | Apr 1972 | A |
3685248 | Godelaine | Aug 1972 | A |
3767085 | Cannon et al. | Oct 1973 | A |
3780935 | Lukacs et al. | Dec 1973 | A |
3800947 | Smith | Apr 1974 | A |
3813072 | Moore | May 1974 | A |
3828980 | Creighton et al. | Aug 1974 | A |
3894952 | Ayres | Jul 1975 | A |
3901402 | Ayres | Aug 1975 | A |
3937219 | Karakashian | Feb 1976 | A |
3976073 | Quick et al. | Aug 1976 | A |
4021352 | Sarstedt et al. | May 1977 | A |
4040420 | Speer | Aug 1977 | A |
4046699 | Zine, Jr. | Sep 1977 | A |
4057499 | Buono | Nov 1977 | A |
4121739 | Devaney et al. | Oct 1978 | A |
4142668 | Lee | Mar 1979 | A |
4184593 | Dorr et al. | Jan 1980 | A |
4202769 | Greenspan | May 1980 | A |
4226235 | Sarnoff et al. | Oct 1980 | A |
4260077 | Schroeder | Apr 1981 | A |
4269174 | Adair | May 1981 | A |
4322298 | Persidsky | Mar 1982 | A |
4355739 | Vierkotter | Oct 1982 | A |
4359049 | Redl et al. | Nov 1982 | A |
4375272 | Sutton, III | Mar 1983 | A |
4413773 | Rohde et al. | Nov 1983 | A |
4424132 | Iriguchi et al. | Jan 1984 | A |
4434820 | Glass | Mar 1984 | A |
4465476 | Gahwiler et al. | Aug 1984 | A |
4467588 | Carveth | Aug 1984 | A |
4498904 | Turner et al. | Feb 1985 | A |
4524770 | Orandi | Jun 1985 | A |
4534511 | Sullivan | Aug 1985 | A |
4540406 | Miles | Sep 1985 | A |
4610666 | Pizzino | Sep 1986 | A |
4627879 | Rose et al. | Dec 1986 | A |
4628969 | Jurgens, Jr. et al. | Dec 1986 | A |
4631055 | Redl et al. | Dec 1986 | A |
4645073 | Homan | Feb 1987 | A |
4650468 | Jennings, Jr. | Mar 1987 | A |
4673395 | Phillips et al. | Jun 1987 | A |
4714457 | Alterbaum | Dec 1987 | A |
4734261 | Koizumi et al. | Mar 1988 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4744955 | Shapiro | May 1988 | A |
4767026 | Keller et al. | Aug 1988 | A |
4818386 | Burns | Apr 1989 | A |
4822340 | Kamstra et al. | Apr 1989 | A |
4826048 | Skorka et al. | May 1989 | A |
4828716 | McEwen et al. | May 1989 | A |
4846800 | Ouriel et al. | Jul 1989 | A |
4874368 | Miller et al. | Oct 1989 | A |
4877520 | Burns | Oct 1989 | A |
4878903 | Mueller | Nov 1989 | A |
4902281 | Avoy | Feb 1990 | A |
4907019 | Stephens | Mar 1990 | A |
4932942 | Maslanka et al. | Jun 1990 | A |
4956883 | Lane | Sep 1990 | A |
4957637 | Cornell | Sep 1990 | A |
4978336 | Capozzi et al. | Dec 1990 | A |
4979942 | Wolf et al. | Dec 1990 | A |
5009342 | Lawrence et al. | Apr 1991 | A |
5032117 | Motta | Jul 1991 | A |
5033252 | Carter | Jul 1991 | A |
5049135 | Davis | Sep 1991 | A |
5074844 | Zdeb et al. | Dec 1991 | A |
5080262 | Herold et al. | Jan 1992 | A |
5080283 | Kukesh et al. | Jan 1992 | A |
5104375 | Wolf et al. | Apr 1992 | A |
5104387 | Pokorney et al. | Apr 1992 | A |
5116315 | Capozzi et al. | May 1992 | A |
5147323 | Haber et al. | Sep 1992 | A |
5152905 | Pall et al. | Oct 1992 | A |
5160021 | Sibley et al. | Nov 1992 | A |
5176658 | Ranford | Jan 1993 | A |
5217118 | Mochizuki et al. | Jun 1993 | A |
5219328 | Morse et al. | Jun 1993 | A |
5226558 | Whitney et al. | Jul 1993 | A |
5226877 | Epstein | Jul 1993 | A |
5226887 | Farr et al. | Jul 1993 | A |
5253785 | Haber et al. | Oct 1993 | A |
5286257 | Fischer | Feb 1994 | A |
5290259 | Fischer | Mar 1994 | A |
5292318 | Haber et al. | Mar 1994 | A |
5298024 | Richmond | Mar 1994 | A |
5300041 | Haber et al. | Apr 1994 | A |
5308041 | Griffioen et al. | May 1994 | A |
5314412 | Rex et al. | May 1994 | A |
5318524 | Morse et al. | Jun 1994 | A |
5322510 | Lindner et al. | Jun 1994 | A |
5332092 | Fischer | Jul 1994 | A |
5354483 | Furse | Oct 1994 | A |
5361906 | Sterett | Nov 1994 | A |
5368563 | Lonneman et al. | Nov 1994 | A |
5372586 | Haber et al. | Dec 1994 | A |
5376079 | Holm et al. | Dec 1994 | A |
5390792 | Van Ness et al. | Feb 1995 | A |
5393497 | Haber et al. | Feb 1995 | A |
5393674 | Levine et al. | Feb 1995 | A |
5405607 | Epstein | Apr 1995 | A |
5409465 | Boggs et al. | Apr 1995 | A |
5411465 | Glen et al. | May 1995 | A |
5419491 | Breitsprecher | May 1995 | A |
5420250 | Lontz | May 1995 | A |
5445614 | Haber et al. | Aug 1995 | A |
5454793 | Levander et al. | Oct 1995 | A |
5458593 | Macabasco et al. | Oct 1995 | A |
5464396 | Barta et al. | Nov 1995 | A |
5474540 | Miller et al. | Dec 1995 | A |
5478323 | Westwood et al. | Dec 1995 | A |
5480068 | Frazier et al. | Jan 1996 | A |
5480378 | Weis-Fogh et al. | Jan 1996 | A |
5484431 | Scharf et al. | Jan 1996 | A |
5505704 | Pawelka et al. | Apr 1996 | A |
5510102 | Cochrum | Apr 1996 | A |
5519422 | Thoman et al. | May 1996 | A |
5519931 | Reich | May 1996 | A |
5520657 | Sellers et al. | May 1996 | A |
5520658 | Holm et al. | May 1996 | A |
5522804 | Lynn | Jun 1996 | A |
5530531 | Girard | Jun 1996 | A |
5542934 | Silver | Aug 1996 | A |
5549246 | Kukesh | Aug 1996 | A |
5549651 | Lynn | Aug 1996 | A |
5562250 | O'Neill | Oct 1996 | A |
5582596 | Fukunaga et al. | Dec 1996 | A |
5585007 | Antanavich et al. | Dec 1996 | A |
5597530 | Smith et al. | Jan 1997 | A |
5605255 | Reidel et al. | Feb 1997 | A |
5605541 | Holm | Feb 1997 | A |
5638661 | Banks | Jun 1997 | A |
5643206 | Fischer | Jul 1997 | A |
5656035 | Avoy | Aug 1997 | A |
5665067 | Linder et al. | Sep 1997 | A |
5697915 | Lynn | Dec 1997 | A |
5728075 | Levander et al. | Mar 1998 | A |
5735465 | Laforcade | Apr 1998 | A |
5752626 | Bachand | May 1998 | A |
5759169 | Marx | Jun 1998 | A |
5759171 | Coelho et al. | Jun 1998 | A |
5792103 | Schwartz et al. | Aug 1998 | A |
5810885 | Zinger et al. | Sep 1998 | A |
5814022 | Antanavich et al. | Sep 1998 | A |
5814066 | Spotnitz | Sep 1998 | A |
5819988 | Sawhney et al. | Oct 1998 | A |
5824012 | Burchett et al. | Oct 1998 | A |
5830547 | MacKenzie et al. | Nov 1998 | A |
5842326 | Wolf | Dec 1998 | A |
5857591 | Bachand | Jan 1999 | A |
5871700 | Konrad | Feb 1999 | A |
5881536 | Muller-Wille et al. | Mar 1999 | A |
5888408 | Nagels | Mar 1999 | A |
5935437 | Whitmore | Aug 1999 | A |
5951517 | Lampropoulos et al. | Sep 1999 | A |
5964377 | Demarest et al. | Oct 1999 | A |
5968018 | Freeman et al. | Oct 1999 | A |
5976102 | Epstein | Nov 1999 | A |
5980866 | Uchida et al. | Nov 1999 | A |
5996847 | Smolen et al. | Dec 1999 | A |
5997811 | Esposito | Dec 1999 | A |
5997881 | Powell et al. | Dec 1999 | A |
6001259 | Whitmore | Dec 1999 | A |
6010034 | Walthers | Jan 2000 | A |
6059749 | Marx | May 2000 | A |
6063055 | Epstein et al. | May 2000 | A |
6079868 | Rydell | Jun 2000 | A |
6099511 | Devos et al. | Aug 2000 | A |
6113571 | Zinger et al. | Sep 2000 | A |
6123687 | Simonyi et al. | Sep 2000 | A |
6132396 | Antanavich et al. | Oct 2000 | A |
6206905 | Holm et al. | Mar 2001 | B1 |
6234994 | Zinger et al. | May 2001 | B1 |
6251370 | Uchida et al. | Jun 2001 | B1 |
6308747 | Farris | Oct 2001 | B1 |
6328229 | Duronio et al. | Dec 2001 | B1 |
6331172 | Epstein et al. | Dec 2001 | B1 |
6394982 | Ehrenfels | May 2002 | B1 |
6461361 | Epstein | Oct 2002 | B1 |
6471670 | Enrenfels et al. | Oct 2002 | B1 |
6475193 | Park et al. | Nov 2002 | B1 |
6479052 | Marshall et al. | Nov 2002 | B1 |
6488650 | Epstein et al. | Dec 2002 | B1 |
6544162 | Van Wie et al. | Apr 2003 | B1 |
6648133 | Blaschke et al. | Nov 2003 | B1 |
6711879 | Korteweg et al. | Mar 2004 | B2 |
6830762 | Baugh et al. | Dec 2004 | B2 |
6959812 | Reif et al. | Nov 2005 | B2 |
6978946 | Sweeton | Dec 2005 | B2 |
7179391 | Leach et al. | Feb 2007 | B2 |
7223346 | Dorian et al. | May 2007 | B2 |
7374678 | Leach et al. | May 2008 | B2 |
7470371 | Dorian et al. | Dec 2008 | B2 |
7766900 | Leach et al. | Aug 2010 | B2 |
8137329 | Romano et al. | Mar 2012 | B2 |
8182769 | Chavarria | May 2012 | B2 |
8420029 | Chavarria | Apr 2013 | B2 |
8444620 | Leach et al. | May 2013 | B2 |
8518272 | Hoeppner | Aug 2013 | B2 |
20010016709 | Tovey et al. | Aug 2001 | A1 |
20020035820 | Farris | Mar 2002 | A1 |
20020104808 | Blasetti et al. | Aug 2002 | A1 |
20020185457 | Smith et al. | Dec 2002 | A1 |
20030023203 | Lavi et al. | Jan 2003 | A1 |
20030029763 | Reif et al. | Feb 2003 | A1 |
20030139774 | Epstein et al. | Jul 2003 | A1 |
20030187408 | Marx | Oct 2003 | A1 |
20030189106 | Cernik | Oct 2003 | A1 |
20030201342 | Foster et al. | Oct 2003 | A1 |
20040024353 | Petersen et al. | Feb 2004 | A1 |
20040035743 | Tighe et al. | Feb 2004 | A1 |
20040065626 | Woo | Apr 2004 | A1 |
20040071786 | Grippi et al. | Apr 2004 | A1 |
20040108338 | Patel | Jun 2004 | A1 |
20040122383 | Romano et al. | Jun 2004 | A1 |
20040209755 | Moore et al. | Oct 2004 | A1 |
20040251217 | Leach et al. | Dec 2004 | A1 |
20050109716 | Leach et al. | May 2005 | A1 |
20050119424 | Ishii et al. | Jun 2005 | A1 |
20050196874 | Dorian et al. | Sep 2005 | A1 |
20050247715 | Ellsworth et al. | Nov 2005 | A1 |
20060009713 | Flaherty | Jan 2006 | A1 |
20060064070 | Martin | Mar 2006 | A1 |
20060175242 | Dorian et al. | Aug 2006 | A1 |
20060196885 | Leach et al. | Sep 2006 | A1 |
20060217674 | Romano et al. | Sep 2006 | A1 |
20060273049 | Leach et al. | Dec 2006 | A1 |
20060273050 | Higgins et al. | Dec 2006 | A1 |
20060278588 | Woodell-May | Dec 2006 | A1 |
20070012623 | Robinson et al. | Jan 2007 | A1 |
20080217264 | Leach et al. | Sep 2008 | A1 |
20080217265 | Leach et al. | Sep 2008 | A1 |
20080283474 | Leach et al. | Nov 2008 | A1 |
20090014391 | Leach et al. | Jan 2009 | A1 |
20090221075 | Dorian et al. | Sep 2009 | A1 |
20090250413 | Hoeppner | Oct 2009 | A1 |
20090253566 | Chavarria | Oct 2009 | A1 |
20100274206 | Leach et al. | Oct 2010 | A1 |
20120228291 | Chavarria | Sep 2012 | A1 |
20130255197 | Chavarria | Oct 2013 | A1 |
20130345038 | Hoeppner | Dec 2013 | A1 |
Number | Date | Country |
---|---|---|
2244697 | Aug 1997 | CA |
2295733 | Jan 1999 | CA |
632579 | Sep 1936 | DE |
807113 | Jun 1951 | DE |
3246999 | May 1984 | DE |
8913761 | Mar 1990 | DE |
29516650 | Jan 1996 | DE |
0208053 | Jan 1987 | EP |
0253418 | Jan 1988 | EP |
0253949 | Jan 1988 | EP |
0292472 | Nov 1988 | EP |
0316284 | May 1989 | EP |
0432871 | Jun 1991 | EP |
0528949 | Mar 1993 | EP |
592242 | Apr 1994 | EP |
0858776 | Aug 1998 | EP |
840257 | Apr 1939 | FR |
2612782 | Sep 1988 | FR |
2661097 | Oct 1991 | FR |
2666986 | Mar 1992 | FR |
2668060 | Apr 1992 | FR |
08238314 | Sep 1996 | JP |
08280802 | Oct 1996 | JP |
09108302 | Apr 1997 | JP |
WO-8807874 | Oct 1988 | WO |
WO-9001959 | Mar 1990 | WO |
WO-9101711 | Feb 1991 | WO |
WO-9117778 | Nov 1991 | WO |
WO-9419038 | Sep 1994 | WO |
WO-9639212 | Dec 1996 | WO |
WO-9725015 | Jul 1997 | WO |
WO-9728834 | Aug 1997 | WO |
WO-9746203 | Dec 1997 | WO |
WO-9747343 | Dec 1997 | WO |
WO-9802098 | Jan 1998 | WO |
WO-9810703 | Mar 1998 | WO |
WO-9810704 | Mar 1998 | WO |
WO-9813094 | Apr 1998 | WO |
WO-9840115 | Sep 1998 | WO |
WO-9901069 | Jan 1999 | WO |
WO-03018425 | Mar 2003 | WO |
Entry |
---|
G. E. Bollin, J. F. Plouffe, M. F. Para and B. Hackman. Aerosols containing Legionella pneumophila generated by shower heads and hot-water faucets. Appl. Environ. Microbiol. 1985, 50(5):1128. |
“The New Gold Standard” brochure for GPS® Mini and GPS® II Platelet Concentrate Separation Kit with ACD-A Anticoagulant, Biomet Biologics, Inc. (Dec. 2006), 7 pages. |
Alving, B.M., M.J. Weinstein, et al. (1995). “Fibrin sealant: summary of a conference on characteristics and clinical uses.” Transfusion 35(9): 783-90. |
B. Braun/McGaw Product Catalog, May 1, 1999. |
CFT Cell Factor Technologies, Inc., GPS® II Platelet Concentrate System, 2004 Biomet Orthopedics, Inc. (10 pages). |
DePuy AcroMed, Inc., Symphony™ Platelet Concentrate System, 2001. |
Developing Technologies for Accelerating Healing, Naturally® , Smart PReP® 2, Harvest® Technologies Corp. 2002 (6 pages). |
Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”. |
DynaStat™, Introducing DynaStat™ Surgical Hemostat—An Innovation in Hemostatic Biodevices, 2000 Cohesion Technologies, Inc. |
FibriJet® 11:1 Ratio Applicator, Micromedics, Inc., printed from www.micromedics-usa.com/products/PDFs/FibriJet—Easy-Assembly.pdf, in 2005 (1 page). |
FibriJet® product sheet, Micromedics, Inc., printed from www.micromedics-usa.com/products/PDFs/product—sheet.pdf, in 2005 (2 pages). |
FibriJet® Ratio Applicator for application of platelet gel, Micromedics, Inc., printed from www.micromedics-usa.com/products/PDFs/ratio.pdf, in 2005 (1 page). |
International Preliminary Examination Report issued Oct. 5, 2010 for PCT/US2009/039488 claiming benefit of U.S. Appl. No. 12/062,817, filed Apr. 4, 2008. |
International Search Report mailed Jul. 10, 2009 for PCT/US2009/039488 claiming benefit of U.S. Appl. No. 12/062,817, filed Apr. 4, 2008. |
Matras, H. (1985). “Fibrin seal: the state of the art.” J Oral Maxillofac Surg 43(8): 605-11. |
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122:37 (1972): 517-523. |
OEM Products Catalog, Merit® Medical, available by Jan. 2003. |
Prof. H. Stütz, M.D., et al., The Use of Autologous Fibrin Glue to Reduce Perioperative Blood Loss in Total Knee Arthroplasty—Results of a Controlled Study, Translated from the original article published in Orthopädische Praxis 40, 12 (2004). |
Redl, H. and G. Schlag (1986). Fibrin Sealant and Its Modes of Application. Fibrin Sealant in Operative Medicine. G. Schlad and H. Redl. Heidelberg, Springer-Verlag: 13-26. |
Redl, H.G. Schlag, et al. (1982). “Methods of Fibrin Seal Application.” Thorac, cardiovasc. Surgeon 30: 223-227. |
Shimada, J.K. Mikami, et al. (1995). “Closure of leaks by fibrin gluing. Effects of various application techniques and temperatures.” J Cardiovac Surg (Torino) 35(2): 181-4. |
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (Apr. 1993): 309-52. |
Sporn, L.A., et al., (1995). “Cell proliferation on fibrin: modulation by fibrinopeptide cleavage.” Blood 86(5): 1802-10. |
Tange, R.A. (1986). “A New Application Method for Fibrin Sealant: The Glue Gun.” Fibrin Sealant in Operative Medicine. G. Schlad and H. Redl. Heidelberg, Springer-Verlag. |
Vox Sanq, vol. 68: 82-89, Feb. 1995, Boomgaard et. al, Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days. |
Number | Date | Country | |
---|---|---|---|
20130324913 A1 | Dec 2013 | US |
Number | Date | Country | |
---|---|---|---|
60654720 | Feb 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12832293 | Jul 2010 | US |
Child | 13899075 | US | |
Parent | 11222303 | Sep 2005 | US |
Child | 12832293 | US |